DVL1 and prostate carcinoma: In prostate cancer, DVL1/2/3 are rarely mutated (<1%), however DVL3 is amplified in up to 2.2% of primary cases, and as many as 8.8% of metastatic cases (Table 1 and Tables S1–S4).